Yield Growth Corp. (CSE: BOSS, OTCQB: BOSQF, Forum) announced on Thursday that its majority owned subsidiary,
NeonMind, filed an additional provisional patent application related to using psychedelics as medicine. This most recent application covers the administration of N,N-Dimethyltryptamine (DMT) to treat compulsive eating disorder and other illnesses.
To learn more about this,
click here.
BOSS’ subsidiary NeonMind had recently filed a US
provisional patent application for the invention relating to therapeutic administration of psilocybin or psilocin (or analogs thereof) combined with supportive therapeutic treatment for a patient to provide weight loss benefits and treatment for related health issues.
FULL DISCLOSURE: Yield Growth Corp. is a client of Stockhouse Publishing.